Literature DB >> 8527282

The accumulation of mercaptopurine metabolites in age fractionated red blood cells.

A Rostami-Hodjegan1, L Lennard, J S Lilleyman.   

Abstract

1. Red blood cells from four children with lymphoblastic leukemia were age fractionated on Percoll density gradients into 'young', 'middle-aged' and 'old' cells. 2. The rates of accumulation of the mercaptopurine (MP) metabolites thioguanine nucleotides (TGNs) and methylmercaptopurine nucleotides (MeMPs) were measured in the cell fractions from the start of MP continuing chemotherapy. 3. TGNs and MeMP metabolites were present in all the red cell fractions after 3 days oral MP. There was no significant difference between the metabolite concentrations measured in either young, middle-aged or old cells (Mann-Whitney P = 1.0 to 0.12). 4. These observations suggest that MP metabolites do not enter red cells at the stem cell level at the start of therapy. 5. With respect to the monitoring of therapy, these results suggest that the concentration of TGNs after 7 to 10 days MP could be used to predict eventual steady-state concentrations using a simple model.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8527282      PMCID: PMC1365100          DOI: 10.1111/j.1365-2125.1995.tb05776.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  25 in total

Review 1.  Incorporation of analog purine nucleosides into the formed elements of human blood: erythrocytes, platelets, and lymphocytes.

Authors:  R E Parks; G W Crabtree; C M Kong; R P Agarwal; K C Agarwal; E M Scholar
Journal:  Ann N Y Acad Sci       Date:  1975-08-08       Impact factor: 5.691

Review 2.  The clinical pharmacology of 6-mercaptopurine.

Authors:  L Lennard
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  The removal of leukocytes and platelets from whole blood.

Authors:  E Beutler; C West; K G Blume
Journal:  J Lab Clin Med       Date:  1976-08

4.  A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine.

Authors:  D M Tidd; A R Paterson
Journal:  Cancer Res       Date:  1974-04       Impact factor: 12.701

Review 5.  Mechanism of red blood cell aging: relationship of cell density and cell age.

Authors:  S Piomelli; C Seaman
Journal:  Am J Hematol       Date:  1993-01       Impact factor: 10.047

6.  Turnover of purine nucleotides in human red blood cells.

Authors:  J Mager; A Dvilansky; A Razin; E Wind; G Izak
Journal:  Isr J Med Sci       Date:  1966 May-Jun

7.  Decrease in S-adenosylmethionine synthesis by 6-mercaptopurine and methylmercaptopurine ribonucleoside in Molt F4 human malignant lymphoblasts.

Authors:  E H Stet; R A De Abreu; J P Bökkerink; H J Blom; L H Lambooy; T M Vogels-Mentink; A C de Graaf-Hess; B van Raay-Selten; F J Trijbels
Journal:  Biochem J       Date:  1994-11-15       Impact factor: 3.857

8.  Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia.

Authors:  L Lennard; B E Gibson; T Nicole; J S Lilleyman
Journal:  Arch Dis Child       Date:  1993-11       Impact factor: 3.791

9.  High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample.

Authors:  L Lennard; H J Singleton
Journal:  J Chromatogr       Date:  1992-11-27

10.  Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia.

Authors:  J S Lilleyman; L Lennard
Journal:  Lancet       Date:  1994-05-14       Impact factor: 79.321

View more
  7 in total

Review 1.  Role of red blood cells in pharmacokinetics of chemotherapeutic agents.

Authors:  Dirk Schrijvers
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Human thiopurine methyltransferase activity varies with red blood cell age.

Authors:  L Lennard; T S Chew; J S Lilleyman
Journal:  Br J Clin Pharmacol       Date:  2001-11       Impact factor: 4.335

3.  Correlation of thiopurine methyltransferase activity and 6-thioguanine nucleotide concentration in Han Chinese patients treated with azathioprine 25 to 100 mg: A 1-year, single-center, prospective study.

Authors:  Bo Zhang; Xiao-Wei Xu; Xue-Jun Zeng; Da-Kui Li
Journal:  Curr Ther Res Clin Exp       Date:  2006-07

4.  IMPDH activity in thiopurine-treated patients with inflammatory bowel disease - relation to TPMT activity and metabolite concentrations.

Authors:  Sofie Haglund; Jan Taipalensuu; Curt Peterson; Sven Almer
Journal:  Br J Clin Pharmacol       Date:  2007-07-27       Impact factor: 4.335

5.  NUDT15 polymorphism and NT5C2 and PRPS1 mutations influence thiopurine sensitivity in acute lymphoblastic leukaemia cells.

Authors:  Shinpei Somazu; Yoichi Tanaka; Minori Tamai; Atsushi Watanabe; Keiko Kagami; Masako Abe; Daisuke Harama; Tamao Shinohara; Koshi Akahane; Kumiko Goi; Kanji Sugita; Takaya Moriyama; Jun Yang; Hiroaki Goto; Masayoshi Minegishi; Shotaro Iwamoto; Junko Takita; Takeshi Inukai
Journal:  J Cell Mol Med       Date:  2021-10-12       Impact factor: 5.310

6.  Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia.

Authors:  Lynne Lennard; Cher Suzanne Cartwright; Rachel Wade; Susan M Richards; Ajay Vora
Journal:  Br J Clin Pharmacol       Date:  2013-07       Impact factor: 4.335

7.  Role of equilibrative nucleoside transporter 1 (ENT1) in the disposition of cytarabine in mice.

Authors:  Jason T Anderson; Shuiying Hu; Qiang Fu; Sharyn D Baker; Alex Sparreboom
Journal:  Pharmacol Res Perspect       Date:  2019-12-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.